We are live on
!
Find out more
Antipodes Partners Portfolio holdings
AUM
$5.46B
Turnover
36.94%
1-Year Est. Return
26.64%
This Fund
S&P 500
This Quarter
Est. Return
+9.77%
1 Year Est. Return
+26.64%
3 Year Est. Return
+96.4%
5 Year Est. Return
+160.76%
10 Year Est. Return
–
AUM
$4.46B
AUM Growth
+$1.23B
(+38%)
Cap. Flow
+$903M
Cap. Flow
% of AUM
20.27%
Top 10 Holdings %
Top 10 Hldgs %
37.6%
Holding
139
New
33
Increased
39
Reduced
42
Closed
23
Avg Time Held Equity + Options
1
year
Top 10 Avg Time Held Equity + Options
1.5
years
Top 20 Avg Time Held Equity + Options
1.5
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
1.5
years
Top 20 Avg Time Held Equity only
1.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ferrovial N.V. Ordinary Shares
FER
|
+$167M |
| 2 |
Exelon
EXC
|
+$156M |
| 3 |
Ameren
AEE
|
+$137M |
| 4 |
Sempra
SRE
|
+$136M |
| 5 |
Crown Castle
CCI
|
+$128M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$108M |
| 2 |
Microsoft
MSFT
|
+$91.6M |
| 3 |
Barrick Mining
B
|
+$63.5M |
| 4 |
Johnson Controls International
JCI
|
+$58.9M |
| 5 |
Capital One
COF
|
+$53.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Utilities | 29.08% |
| 2 | Healthcare | 12.43% |
| 3 | Technology | 11.96% |
| 4 | Financials | 8.08% |
| 5 | Materials | 7.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Oric Pharmaceuticals
ORIC
$1.32B
| $34.8K | ﹤0.01% |
2,901
-2,293
| -44% | -$24.1K |
2025 Q1
2 quarters
|
|
102
DELISTED
Nuvalent
NUVL
| $33.8K | ﹤0.01% |
391
-88
| -18% | -$6.96K |
2025 Q1
2 quarters
|
|
103
Stryker
SYK
$112B
| $33.6K | ﹤0.01% |
+91
| New | +$35.2K |
2025 Q3
0 quarters
|
|
104
DELISTED
Apogee Therapeutics
APGE
| $33.5K | ﹤0.01% |
843
+246
| +41% | +$9.39K |
2025 Q1
2 quarters
|
|
105
Janux Therapeutics
JANX
$1.06B
| $32.9K | ﹤0.01% |
1,344
+296
| +28% | +$7.21K |
2025 Q1
2 quarters
|
|
106
Waystar Holding Corp
WAY
$5.41B
| $31.2K | ﹤0.01% |
823
+449
| +120% | +$16.6K |
2025 Q2
1 quarter
|
|
107
DELISTED
Amicus Therapeutics
FOLD
| $30.9K | ﹤0.01% |
+3,926
| New | +$27.9K |
2025 Q3
0 quarters
|
|
108
Danaher
DHR
$163B
| $27.2K | ﹤0.01% |
+137
| New | +$27.3K |
2025 Q3
0 quarters
|
|
109
Waters Corp
WAT
$43.6B
| $26.4K | ﹤0.01% |
+88
| New | +$26.6K |
2025 Q3
0 quarters
|
|
110
Sagimet Biosciences
SGMT
$579M
| $21.8K | ﹤0.01% |
3,176
-2,236
| -41% | -$18.1K |
2025 Q2
1 quarter
|
|
111
IDEAYA Biosciences
IDYA
$3.27B
| $21K | ﹤0.01% |
+770
| New | +$18.6K |
2025 Q3
0 quarters
|
|
112
Humacyte
HUMA
$122M
| $14.1K | ﹤0.01% |
8,125
+951
| +13% | +$1.86K |
2025 Q2
1 quarter
|
|
113
Array Technologies
ARRY
$550M
| $14K | ﹤0.01% |
1,715
+457
| +36% | +$3.46K |
2024 Q3
4 quarters
|
|
114
DELISTED
Day One Biopharmaceuticals
DAWN
| $12.2K | ﹤0.01% |
1,731
-1,275
| -42% | -$8.77K |
2025 Q1
2 quarters
|
|
115
Sociedad Química y Minera de Chile
SQM
$17.3B
| $7.82K | ﹤0.01% |
182
-49
| -21% | -$2.04K |
2025 Q2
1 quarter
|
|
116
Shoals Technologies Group
SHLS
$1.31B
| $7.25K | ﹤0.01% |
+978
| New | +$6.02K |
2025 Q3
0 quarters
|
|
117
Booz Allen Hamilton
BAH
$8.96B
| – | – |
-16,409
| Closed | -$1.71M | – |
|
118
Century Aluminum
CENX
$3.39B
| – | – |
-153,131
| Closed | -$2.76M | – |
|
119
Core Scientific
CORZ
$4.65B
| – | – |
-1,391
| Closed | -$23.7K | – |
|
120
Criteo S.A.
CRTO
$772M
| – | – |
-608,302
| Closed | -$14.6M | – |
|
121
Cemex
CX
$14.5B
| – | – |
-6,018,838
| Closed | -$41.7M | – |
|
122
DELISTED
American Express Global Business Travel
GBTG
| – | – |
-32,085
| Closed | -$202K | – |
|
123
VanEck Gold Miners ETF
GDX
$26.1B
| – | – |
-64,741
| Closed | -$3.37M | – |
|
124
VanEck Junior Gold Miners ETF
GDXJ
$8.12B
| – | – |
-58,457
| Closed | -$3.95M | – |
|
125
Lumen Technologies, Inc. Common Stock
LUMN
$5.02B
| – | – |
-11,386
| Closed | -$49.9K | – |
|
Similar funds
SCM
Antipodes Partners's Q3 2025 Portfolio in Review
As of Q3 2025, Antipodes Partners held 139 positions worth $4.46B, up 38% from $3.22B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Antipodes Partners deployed $903M of net new capital in Q3 2025, opening 33 new positions and adding to 39 existing holdings. Its largest new stake was Ferrovial N.V. Ordinary Shares: 3,097,701 shares worth $176M.
By sector, the portfolio is most concentrated in Utilities at 29% of assets, up from 3.7% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Alphabet (Google) Class A, an estimated $108M trimmed.
- Antipodes Partners's largest Q3 2025 buy was Ferrovial N.V. Ordinary Shares: 3,097,701 shares worth $176M.
- Antipodes Partners added most to Exelon in Q3 2025, an estimated $156M increase.
- Antipodes Partners's biggest Q3 2025 reduction was Alphabet (Google) Class A, cutting an estimated $108M.
- Antipodes Partners fully exited Micron Technology in Q3 2025, selling an estimated $49.7M.
- Antipodes Partners's ten largest holdings make up 38% of its $4.46B portfolio in Q3 2025.
- Antipodes Partners opened 33 new positions and closed 23 in Q3 2025.
- Antipodes Partners's portfolio value rose 38% quarter-over-quarter to $4.46B.
Based on Antipodes Partners's 13F filing for Q3 2025, filed 10 Nov 2025.